Emergent BioSolutions Inc., a pharmaceutical company, has initiated the Phase II clinical trial for NuThrax or AV7909, with the dosing of the first subject.
NuThrax, a next generation vaccine being developed as part of Emergent’s anthrax franchise, consists of Anthrax Vaccine Adsorbed in combination with a novel immune stimulatory adjuvant, CPG 7909.
{iframe}http://www.equities.com/news/headline-story?dt=2013-01-22&val=950410&cat=hcare{/iframe}